-
肝细胞肝癌(hepatocellular carcinoma,HCC)是常见的恶性肿瘤之一,病死率较高。18F-FDG PET/CT显像常用于恶性肿瘤的诊断、临床分期及预后评估,但其诊断原发HCC的灵敏度不高,假阴性率可达40%~50%[1]。18F-FDG与11C-乙酸盐PET/CT显像具有一定程度的互补性,常用于HCC的诊断[2]、临床分期[3-4]及肝脏肿瘤的鉴别诊断[5-6]。先前关于18F-FDG及11C-乙酸盐双示踪剂在HCC患者中的应用研究中包含了低、中、高分化的HCC 3种不同分化类型,并未对特定的病理类型选择不同示踪剂进行显像[2, 7-8]。笔者仅对中、高分化HCC患者进行双示踪剂显像,初步探讨11C-乙酸盐单示踪剂PET/CT显像能否取代双示踪剂显像用于监测中、高分化HCC患者的复发与转移。
-
10例中、高分化HCC患者的临床资料及11C-乙酸盐、18F-FDG显像结果见表 1。11C-乙酸盐显像发现18个阳性病灶,灵敏度为100%(18/18);18F-FDG显像发现5个阳性病灶,灵敏度为27.8%(5/18);两种示踪剂同时发现5个阳性病灶(在4例中分化HCC患者中),11C-乙酸盐显像探测病灶的灵敏度与双示踪剂联合显像相同。18F-FDG显像发现2例中分化(图 1)和4例高分化HCC(图 2)病灶显像为阴性。11C-乙酸盐显像病灶的SUVmax为1.3~14.2,靶/本底比值(the ratio of target to background,T/B)为1.1~14.3;18F-FDG显像病灶的SUVmax为0.5~3.4,T/B为0.6~1.1。8例患者(13个病灶)病理证实为肿瘤复发或转移,2例患者(5个病灶)3个月后我院复查PET/CT或CT证实为转移。
序号 年龄 肝炎病史 AFP/
(μg/L)病理类型 病灶数目 病变位置 病变大小/
(cm×cm)11C-乙酸盐 18F-FDG SUVmax T/B 阳性(+)/
阴性(-)SUVmax T/B 阳性(+)/
阴性(-)1 46 + 263.56 中分化 2 肝内 2.7×2.0 4.0 1.2 + 3.4 1.1 + 肝内 4.3×2.4 4.4 1.3 + 3.4 1.1 + 2 51 + 102.82 中分化 2 肝内 1.3×0.9 5.7 1.8 + 2.4 0.9 - 肝内 2.7×2.0 5.1 1.6 + 2.8 1.1 + 3 69 + 97.1 高分化 1 肝内 1.0×0.8 3.9 1.1 + 1.8 0.6 - 4 56 + 223.62 中分化 1 肝内 9.0×6.8 6.0 1.4 + 2.5 0.9 - 5 74 + 69.81 高分化 1 肝内 9.8×7.7 14.2 3.2 + 3.3 0.9 - 6 53 + > 24 200 中分化 2 肝内 2.9×2.2 4.2 1.5 + 3.1 0.8 - 肝内 1.6×1.2 6.2 2.2 + 3.2 1.1 + 7 49 + 476.09 中分化 1 肝内 2.1×1.6 4.5 1.6 + 2.7 0.9 - 8 67 + 81.62 高分化 2 肝内 3.1×2.5 6.7 1.7 + 2.9 1 - 肝内 2.1×1.9 5.8 1.5 + 3 0.9 - 9 27 + 611.42 中分化 2 肝内 2.4×1.4 7.1 1.8 + 2.8 1 - 肝内 2.2×1.4 6.5 1.7 + 3 1.1 + 10 63 + 371.5 高分化 4 肝内 1.6×1.1 3.9 1.6 + 3 1 - 脾门区 3.0×1.6 4.3 14.3 + 0.6 1 - 腹膜后 1.5×1.3 5.5 9.2 + 0.5 0.8 - 小网膜 0.9×0.7 1.3 3.3 + 0.6 1 - 注:表中,“+”为阳性,为阴性;FDG:氟脱氧葡萄糖;PET/CT:正电子发射断层显像计算机体层摄影术;AFP:甲胎蛋白; SUVmax:最大标准化摄取值;T/B:靶/本底比值 表 1 10例男性中、高分化肝细胞肝癌患者的临床资料及11C-乙酸盐、18F-FDG PET/CT显像结果
Table 1. Clinical data and 11C-acetate and 18F-FDG PET/CT results of 10 male cases of moderately and highly differentiated hepatocellular carcinoma
11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究
Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation
-
摘要:
目的探讨11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌(HCC)复发与转移监测中的应用价值。 方法回顾性分析2015年1月至2016年12月行11C-乙酸盐和18F-FDG PET/CT躯干显像的10例中、高分化HCC男性患者,其中,中分化HCC 6例,高分化HCC 4例。患者经手术或介入治疗后,甲胎蛋白进行性升高,比较11C-乙酸盐和18F-FDG PET/CT的诊断价值。PET图像上代谢高于正常肝脏组织的病灶判定为阳性,低于或类似于正常肝脏组织的病灶判定为阴性。通过勾画感兴趣区计算病灶及本底最大标准化摄取值(SUVmax)及靶/本底比值(T/B)。所有患者最终通过病理或影像学检查确诊转移或复发。 结果11C-乙酸盐显像发现18个阳性病灶,灵敏度为100%(18/18);18F-FDG显像发现5个阳性病灶,灵敏度为27.8%(5/18);两种示踪剂同时发现5个阳性病灶(在4例中分化HCC患者中),11C-乙酸盐显像探测病灶的灵敏度与两种示踪剂联合显像相同。11C-乙酸盐显像病灶SUVmax为1.3~14.2,T/B为1.1~14.3;18F-FDG显像病灶SUVmax为0.5~3.4,T/B为0.6~1.1。8例患者(13个病灶)病理证实为肿瘤复发或转移,2例患者(5个病灶)3个月后复查PET/CT或CT证实为转移。 结论11C-乙酸盐显像可显著提高中、高分化HCC复发与转移诊断的灵敏度;推荐使用11C-乙酸盐显像用于监测中、高分化HCC的复发与转移。 -
关键词:
- 癌,肝细胞 /
- 氟脱氧葡萄糖F18 /
- 乙酸盐类 /
- 正电子发射断层显像计算机体层摄影术
Abstract:ObjectivesTo investigate the value of 11C-acetate PET/CT imaging in the detection of the recurrence and metastasis of hepatocellular carcinoma (HCC) with high or medium differentiation. MethodsA total of 10 patients who underwent surgical or interventional therapy, had moderately or highly differentiated HCC, underwent 11C-acetate and 18F-FDG PET/CT trunk imaging from January 2015 to December 2016 were retrospectively analyzed. Progressive increases in alpha fetoprotein were observed in the patients after the treatment. 11C-acetate and 18F-FDG PET/CT scan were performed on the patients in one week, and the diagnostic values of the two tracers were compared. In the PET images, the lesion was positive when the metabolic level of the lesion was higher than that of a normal liver tissue and negative when the metabolic level of the lesion was lower than or same as that of a normal liver tissue. The maximum standardized uptake value(SUVmax) and the ratio of target to background(T/B) were calculated by outlining the areas of interest. All patients were diagnosed with metastasis or recurrence by pathology or imaging examination. ResultsSix patients had moderately differentiated HCC and four patients had highly differentiated HCC. 11C-acetate imaging revealed 18 positive lesions, and the sensitivity was 100%(18/18). Five positive lesions were found in 18F-FDG images, and the sensitivity was 27.8%(5/18). Two tracers revealed five positive lesions (in four patients with moderately differentiated HCC). The sensitivity of 11C-acetate imaging to detect lesions was the same as that of double tracers combined imaging. The SUVmax range of 11C-acetate imaging was 1.3-14.2, and the range of T/B was 1.1-14.3. The SUVmax range of 18F-FDG imaging was 0.5-3.4, and the range of T/B was 0.6-1.1. Eight patients (13 lesions) were pathologically confirmed to have tumor recurrence or metastasis, and two patients (5 lesions) proved to be metastatic after 3 months of follow-up. Conclusions11C-acetate imaging can significantly improve the sensitivity of the diagnosis of recurrence and metastasis of moderately and highly differentiated HCC. 11C-acetate imaging is expected to replace 18F-FDG imaging in monitoring recurrence and metastasis in moderately and highly differentiated HCC. -
表 1 10例男性中、高分化肝细胞肝癌患者的临床资料及11C-乙酸盐、18F-FDG PET/CT显像结果
Table 1. Clinical data and 11C-acetate and 18F-FDG PET/CT results of 10 male cases of moderately and highly differentiated hepatocellular carcinoma
序号 年龄 肝炎病史 AFP/
(μg/L)病理类型 病灶数目 病变位置 病变大小/
(cm×cm)11C-乙酸盐 18F-FDG SUVmax T/B 阳性(+)/
阴性(-)SUVmax T/B 阳性(+)/
阴性(-)1 46 + 263.56 中分化 2 肝内 2.7×2.0 4.0 1.2 + 3.4 1.1 + 肝内 4.3×2.4 4.4 1.3 + 3.4 1.1 + 2 51 + 102.82 中分化 2 肝内 1.3×0.9 5.7 1.8 + 2.4 0.9 - 肝内 2.7×2.0 5.1 1.6 + 2.8 1.1 + 3 69 + 97.1 高分化 1 肝内 1.0×0.8 3.9 1.1 + 1.8 0.6 - 4 56 + 223.62 中分化 1 肝内 9.0×6.8 6.0 1.4 + 2.5 0.9 - 5 74 + 69.81 高分化 1 肝内 9.8×7.7 14.2 3.2 + 3.3 0.9 - 6 53 + > 24 200 中分化 2 肝内 2.9×2.2 4.2 1.5 + 3.1 0.8 - 肝内 1.6×1.2 6.2 2.2 + 3.2 1.1 + 7 49 + 476.09 中分化 1 肝内 2.1×1.6 4.5 1.6 + 2.7 0.9 - 8 67 + 81.62 高分化 2 肝内 3.1×2.5 6.7 1.7 + 2.9 1 - 肝内 2.1×1.9 5.8 1.5 + 3 0.9 - 9 27 + 611.42 中分化 2 肝内 2.4×1.4 7.1 1.8 + 2.8 1 - 肝内 2.2×1.4 6.5 1.7 + 3 1.1 + 10 63 + 371.5 高分化 4 肝内 1.6×1.1 3.9 1.6 + 3 1 - 脾门区 3.0×1.6 4.3 14.3 + 0.6 1 - 腹膜后 1.5×1.3 5.5 9.2 + 0.5 0.8 - 小网膜 0.9×0.7 1.3 3.3 + 0.6 1 - 注:表中,“+”为阳性,为阴性;FDG:氟脱氧葡萄糖;PET/CT:正电子发射断层显像计算机体层摄影术;AFP:甲胎蛋白; SUVmax:最大标准化摄取值;T/B:靶/本底比值 -
[1] Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses[J]. J Nucl Med, 2003, 44(2):213-221. [2] Larsson P, Arvidsson D, Björnstedt M, et al. Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma[J]. Mol Imaging Radionucl Ther, 2012, 21(1):6-12. DOI:10.4274/Mirt.87. [3] Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria:surgeon's perspective[J]. J Nucl Med, 2013, 54(2):192-200. DOI:10.2967/jnumed.112.107516. [4] Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12):1912-1921. DOI:10.2967/jnumed.108.055087. [5] Huo L, Dang Y, Lv J, et al. Application of dual phase imaging of 11C-acetate positron emission tomography on differential diagnosis of small hepatic lesions[J/OL]. PLoS One, 2014, 9(5): e96517[2018-01-12]. https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC4015995. DOI: 10.1371/journal.pone.0096517. [6] Magini G, Farsad M, Frigerio M, et al. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma[J]. Clin Nucl Med, 2009, 34(10):659-665. DOI:10.1097/RLU.0b013e3181b53488. [7] Ho CL, Chen S, Cheng TK, et al. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma[J]. Radiology, 2011, 258(2):515-523. DOI:10.1148/radiol.10100672. [8] Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma[J]. J Nucl Med, 2007, 48(6):902-909. DOI:10.2967/jnumed.106.036673. [9] Yoon KT, Kim JK, Kim DY, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma[J]. Oncology, 2007, 72 Suppl 1:S104-110. DOI:10.1159/000111715. [10] Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation:acetate metabolism in tumor cells[J]. Nucl Med Biol, 2001, 28(2):117-122. doi: 10.1016/S0969-8051(00)00195-5 [11] Salem N, Kuang Y, Corn D, et al.[(Methyl)1-11C]-acetate metabolism in hepatocellular carcinoma[J]. Mol Imaging Biol, 2011, 13(1):140-151. DOI:10.1007/s11307-010-0308-y. [12] Polanec SH, Andrzejewski P, Baltzer PAT, et al. Multiparametric[11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer[J/OL]. PLoS One, 2017, 12(7): e0180790[2018-01-12]. https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC5515396. DOI: 10.1371/journal.pone.0180790. [13] Ho CL, Chen S, Ho KM, et al. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma[J]. Clin Nucl Med, 2012, 37(11):1075-1082. DOI:10.1097/RLU.0b013e318266-cde2.